James D Marks

List of Publications by Year
in descending order

37 papers	**1,031** citations	471509 **17** h-index	434195 **31** g-index
38 all docs	**38** docs citations	**38** times ranked	**1135** citing authors

#	Article	IF	Citations
1	A Monoclonal Antibody Combination against both Serotypes A and B Botulinum Toxin Prevents Inhalational Botulism in a Guinea Pig Model. Toxins, 2021, 13, 31.	3.4	6
2	Neutralizing Concentrations of Anti-Botulinum Toxin Antibodies Positively Correlate with Mouse Neutralization Assay Results in a Guinea Pig Model. Toxins, 2021, 13, 671.	3.4	5
3	A Four-Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotypes C and D. Toxins, 2021, 13, 641.	3.4	6
4	The Novel Clostridial Neurotoxin Produced by Strain IBCA10-7060 Is Immunologically Equivalent to BoNT/HA. Toxins, 2020, 12, 9.	3.4	16
5	Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic. Pharmaceutics, 2020, 12, 996.	4.5	6
6	Pharmacokinetics of Human Recombinant Anti-Botulinum Toxin Antibodies in Rats. Toxins, 2019, 11, 345.	3.4	8
7	Safety and Pharmacokinetics of a Four Monoclonal Antibody Combination against Botulinum C and D Neurotoxins. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	15
8	Monoclonal Antibody Combinations Prevent Serotype A and Serotype B Inhalational Botulism in a Guinea Pig Model. Toxins, 2019, 11, 208.	3.4	18
9	Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models. Nature Biomedical Engineering, 2019, 3, 264-280.	22.5	40
10	Antibody engineering to improve manufacturability. Protein Expression and Purification, 2018, 149, 75-83.	1.3	8
11	Discovery of internalizing antibodies to basal breast cancer cells. Protein Engineering, Design and Selection, 2018, 31, 17-28.	2.1	4
12	A Single Tri-Epitopic Antibody Virtually Recapitulates the Potency of a Combination of Three Monoclonal Antibodies in Neutralization of Botulinum Neurotoxin Serotype A. Toxins, 2018, 10, 84.	3.4	8
13	A Three Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotype E Subtypes. Toxins, 2018, 10, 105.	3.4	30
14	Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting. MAbs, 2017, 9, 58-67.	5.2	23
15	A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype F subtypes. PLoS ONE, 2017, 12, e0174187.	2.5	27
16	Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H. Journal of Infectious Diseases, 2016, 213, 1606-1614.	4.0	36
17	Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B. Toxins, 2015, 7, 3405-3423.	3.4	18
18	A fully human scFv phage display library for rapid antibody fragment reformatting. Protein Engineering, Design and Selection, 2015, 28, 307-316.	2.1	22

#	Article	IF	Citations
19	Monoclonal Antibodies Targeting the Alpha-Exosite of Botulinum Neurotoxin Serotype/A Inhibit Catalytic Activity. PLoS ONE, 2015, 10, e0135306.	2.5	15
20	Checklists and Other Cognitive Aids For Emergency And Routine Anesthesia Care-A Survey on the Perception of Anesthesia Providers From a Large Academic US Institution. Anesthesiology and Pain Medicine, 2015, 5, e26300.	1.3	20
21	High Throughput Identification of Monoclonal Antibodies to Membrane Bound and Secreted Proteins Using Yeast and Phage Display. PLoS ONE, 2014, 9, e111339.	2.5	15
22	Combining Anti-ERBB3 Antibodies Specific for Domain I and Domain III Enhances the Anti-Tumor Activity over the Individual Monoclonal Antibodies. PLoS ONE, 2014, 9, e112376.	2.5	11
23	Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific 64Cu-DOTA conjugation. Protein Engineering, Design and Selection, 2014, 27, 317-324.	2.1	27
24	Anti-MET ImmunoPET for Nonâ€"Small Cell Lung Cancer Using Novel Fully Human Antibody Fragments. Molecular Cancer Therapeutics, 2014, 13, 2607-2617.	4.1	29
25	Selection of improved peptide ligases by yeast surface display. FASEB Journal, 2012, 26, 549.3.	0.5	0
26	A Single-Domain Llama Antibody Potently Inhibits the Enzymatic Activity of Botulinum Neurotoxin by Binding to the Non-Catalytic Î±-Exosite Binding Region. Journal of Molecular Biology, 2010, 397, 1106-1118.	4.2	78
27	Extraction of BoNT/A, /B, /E, and /F with a Single, High Affinity Monoclonal Antibody for Detection of Botulinum Neurotoxin by Endopep-MS. PLoS ONE, 2010, 5, e12237.	2.5	53
28	Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nature Biotechnology, 2007, 25, 107-116.	17.5	165
29	PCR Cloning of Human Immunoglobulin Genes. , 2004, 248, 117-134.		14
30	Antibody Affinity Maturation by Chain Shuffling. , 2004, 248, 327-344.		18
31	Selection of Human Antibodies from Phage Display Libraries. , 2004, 248, 161-176.		41
32	Selection of Internalizing Antibodies for Drug Delivery. , 2004, 248, 201-208.		12
33	Medical aspects of biologic toxins. Anesthesiology Clinics, 2004, 22, 509-532.	1.4	33
34	Infectious Disease and Bioterrorism. Anesthesiology Clinics, 2004, 22, xiii-xv.	1.4	0
35	Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization. Movement Disorders, 2004, 19, S101-S108.	3.9	68
36	Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells. Cancer Gene Therapy, 2001, 8, 555-565.	4.6	65

#	Article	IF	Citations
37	Efficient in vitro affinity maturation of phage antibodies using BIAcore guided selections. Human Antibodies, 1996, 7, 97-105.	1.5	69